These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30177497)

  • 1. Baseline corticosteroids reduce activity of PD-L1 blockade.
    Gourd E
    Lancet Oncol; 2018 Oct; 19(10):e515. PubMed ID: 30177497
    [No Abstract]   [Full Text] [Related]  

  • 2. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 3. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW; Chaft J; Hellmann M
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract]   [Full Text] [Related]  

  • 4. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
    Patel JD; Chmura SJ
    Cancer; 2018 Jul; 124(14):2878-2880. PubMed ID: 29906817
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
    Remon J; Reguart N; Auclin E; Besse B
    J Thorac Oncol; 2019 Jun; 14(6):963-967. PubMed ID: 31027971
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.
    Hwang WL; Niemierko A; Hwang KL; Hubbeling H; Schapira E; Gainor JF; Keane FK
    JAMA Oncol; 2018 Feb; 4(2):253-255. PubMed ID: 28973343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
    Arbour KC; Mezquita L; Long N; Rizvi H; Auclin E; Ni A; Martínez-Bernal G; Ferrara R; Lai WV; Hendriks LEL; Sabari JK; Caramella C; Plodkowski AJ; Halpenny D; Chaft JE; Planchard D; Riely GJ; Besse B; Hellmann MD
    J Clin Oncol; 2018 Oct; 36(28):2872-2878. PubMed ID: 30125216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.
    Mountzios G; Remon J; Novello S; Blais N; Califano R; Cufer T; Dingemans AM; Liu SV; Peled N; Pennell NA; Reck M; Rolfo C; Tan D; Vansteenkiste J; West H; Besse B
    Ann Oncol; 2019 Nov; 30(11):1686-1688. PubMed ID: 31504132
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.
    Sibille A; Henket M; Corhay JL; Louis R; Duysinx B
    Acta Oncol; 2020 Mar; 59(3):257-259. PubMed ID: 31755328
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
    Prelaj A; Tay R; Ferrara R; Chaput N; Besse B; Califano R
    Eur J Cancer; 2019 Jan; 106():144-159. PubMed ID: 30528799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    Tachihara M; Negoro S; Inoue T; Tamiya M; Akazawa Y; Uenami T; Urata Y; Hattori Y; Hata A; Katakami N; Yokota S
    BMC Cancer; 2018 Oct; 18(1):946. PubMed ID: 30285770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
    Check JH; Check D; Poretta T
    Anticancer Res; 2019 Apr; 39(4):1923-1926. PubMed ID: 30952734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
    Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T
    Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
    Woodford R; Loh Y; Lee J; Cooper W; Marschner I; Lewis CR; Millward M; Lord S; Gralla RJ; Yang JC; Mok T; Lee CK
    Future Oncol; 2019 Jul; 15(20):2371-2383. PubMed ID: 31354046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic approaches for small-cell lung cancer.
    Iams WT; Porter J; Horn L
    Nat Rev Clin Oncol; 2020 May; 17(5):300-312. PubMed ID: 32055013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approves 2 Therapies for Treatment of Metastatic Non-Small Cell Lung Cancer.
    Wright KM
    Oncology (Williston Park); 2020 Jun; 34(6):202. PubMed ID: 32609866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immuno-checkpoint inhibitor resistance and strategy in lung cancer].
    Jiang WR; Fang LP; Chang N; Zhang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jul; 43(7):603-606. PubMed ID: 32629564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
    Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
    Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.